Three FDA-approved medications,naltrexone, acamprosate, and disulfiram,are transforming how doctors treat alcohol use disorder by targeting different aspects of addiction, from brain chemistry to physical deterrents. When combined with behavioral therapy and counseling, these medications help reduce cravings, ease the discomfort of early sobriety, and support long-term recovery in ways that therapy alone cannot achieve.

Why Medication-Assisted Treatment Works Better Than Therapy Alone?

Research consistently shows that individuals who receive medication-assisted treatment (MAT) for alcohol addiction have better outcomes than those relying on behavioral therapy alone. Medication-assisted treatment combines FDA-approved medications with behavioral therapies and counseling to address the biological and psychological roots of addiction. Despite proven effectiveness, many people remain unaware that medications exist to help reduce cravings, prevent relapse, and support long-term sobriety. These medications are not cures, but powerful tools that work best as part of a comprehensive treatment plan that includes therapy, peer support, and lifestyle changes.

How Do These Three Medications Address Alcohol Addiction Differently?

• Naltrexone: Available as a daily pill or monthly injection called Vivitrol, naltrexone blocks opioid receptors in the brain to reduce the pleasurable effects of drinking. This diminishes cravings and the urge to continue drinking after the first sip, making it especially valuable for people who struggle with intense cravings or the "one drink leads to many" pattern. The landmark COMBINE study demonstrated that naltrexone significantly reduces heavy drinking days and supports longer periods of abstinence.
• Acamprosate: Sold under the brand name Campral, acamprosate works by stabilizing the brain's chemical balance after a person stops drinking. Rather than reducing the pleasurable effects of alcohol, it eases the discomfort of early recovery by reducing anxiety, insomnia, and restlessness that make abstinence difficult to maintain. It is best suited for people who have already completed detox and are fully abstinent, and it is processed by the kidneys rather than the liver, making it a good option for those with liver problems.
• Disulfiram: Commonly known by the brand name Antabuse, disulfiram creates a powerful physical deterrent by causing highly unpleasant reactions,including flushing, nausea, vomiting, and rapid heartbeat,when a person taking it consumes alcohol. This aversion therapy approach motivates people to avoid alcohol entirely and is most effective when there is strong motivation to stop drinking and consistent medication adherence under medical supervision.

Each medication addresses alcohol use disorder from a different angle. Choosing the right one depends on individual factors including drinking patterns, medical history, motivation level, and personal goals. There is no one-size-fits-all approach, which is why working with an experienced addiction treatment team is essential.

What Are the Side Effects and Considerations for Each Medication?

Naltrexone may cause nausea, fatigue, headache, and dizziness when first starting, though most side effects are mild and improve with time. It does not cause dependence and is not a controlled substance, making it a safe long-term option for many people. Naltrexone may be a good option for individuals who are motivated to reduce or stop drinking, are not currently dependent on opioids, and do not have significant liver disease. It is one of the first-line medications recommended by the National Institute on Alcohol Abuse and Alcoholism (NIAAA).

Acamprosate requires three daily doses and is particularly helpful for people whose main challenge is getting through the difficult emotional and physical adjustment period after stopping alcohol. When combined with counseling and support groups, acamprosate can be a cornerstone of a long-term recovery plan.

Disulfiram requires a firm commitment because even small amounts of alcohol,including alcohol found in certain foods, mouthwashes, and medications,can trigger a reaction. Regular monitoring by a healthcare provider is important when using disulfiram. It may not be appropriate for individuals with certain heart conditions, liver disease, or mental health concerns. A comprehensive evaluation by an addiction medicine professional is essential before beginning this medication.

How to Build a Comprehensive Recovery Plan?

• Combine medication with behavioral therapy: Medications work best when paired with evidence-based therapies such as cognitive behavioral therapy (CBT), motivational interviewing, and contingency management to help individuals identify triggers, develop coping strategies, and build a sustainable sober lifestyle.
• Address co-occurring mental health conditions: Alcohol use disorder frequently co-occurs with anxiety, depression, trauma, and other mental health conditions. A dual diagnosis treatment approach that addresses both the addiction and underlying mental health issues tends to produce the best outcomes.
• Engage in support groups and family therapy: Support groups, family therapy, and mental health services play a vital role in long-term recovery. True healing requires treating the whole person, not just the symptoms of addiction.

The existence of FDA-approved, evidence-based medications like naltrexone, acamprosate, and disulfiram is a testament to how far science has come in understanding and treating alcohol use disorder. These tools, combined with compassionate professional support, can change lives.

What New Treatments Are on the Horizon?

Beyond these established medications, researchers are exploring innovative approaches to reduce cravings. The U.S. Food and Drug Administration (FDA) recently cleared an experimental drug called ANS-858 to enter clinical trials for alcohol use disorder and other substance use disorders. ANS-858 works by temporarily blocking an enzyme called aldehyde dehydrogenase 2 (ALDH2), which plays a role in how the body processes alcohol. Research suggests that ALDH2 may be involved in the biological processes behind cravings, making it a promising target for new treatments.

"FDA clearance of our IND for ANS-858 represents an important milestone for Amygdala Neurosciences and our first-in-class ALDH2 therapeutic platform," said Brent Blackburn, Chief Executive Officer of Amygdala Neurosciences.

Brent Blackburn, Chief Executive Officer, Amygdala Neurosciences

The significance of targeting cravings cannot be overstated. In a 2022 study, most participants in recovery from alcohol use disorder who experienced relapses reported that cravings occurred alongside those lapses at least 92% of the time. If ANS-858 can lessen the urge to use substances, researchers hope it could support people during treatment and throughout recovery, helping them maintain their progress and reduce the risk of relapse. The company plans to study ANS-858 as a once-daily oral medication during clinical trials.

For people currently experiencing problematic drinking or alcohol use disorder, evidence-based treatments remain the best option. If you or someone you love is struggling with alcohol addiction, help is available and recovery is absolutely possible. Taking that first step toward getting help is one of the most courageous acts a person can take.